Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted the price target on the stock to $40 from $37 while keeping an Underweight rating on the shares. The firm told investors in a research note that while the 2026 revenue and EPS guidance exceeded consensus, it was driven by a higher-than-expected Eliquis guide.

In addition to Morgan Stanley, BofA also raised the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $68 from $64 on February 6 and maintained a Buy rating on the shares. The firm lifted its near-term forecasts after the company delivered fiscal Q4 and FY26 guidance beats, telling investors that  Bristol-Myers Squibb Company (NYSE:BMY) “is a pipeline story”.

The same day, Guggenheim also raised the price target on the stock to $72 from $62, maintaining a Buy rating on the shares and raising its view of the odds of success to 90% for iber/mezi from the previous 33%. The firm also increased its view of the odds of success to 90% from 75% prior for milvexian in SSP, stating that it is continuing to recommend that investors buy shares ahead of the company’s “series of high-profile, potentially high-reward” Phase 3 catalysts.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.